Statement from Bayer HealthCare on Completion of Enrollment in REMox TB

January 31, 2012

Dr. Martin Springsklee

Vice President - Head Global Medical Affairs Anti-Infectives at Bayer HealthCare

We started our partnership with the TB Alliance with a distinct aim: to assess whether the standard therapy period of six months in the treatment of pulmonary tuberculosis could be reduced by the use of an already existing antibiotic, moxifloxacin. The completion of patient enrollment in the REMox TB study is a significant milestone on the way to potentially reducing the therapy period and thus helping to reduce the alarmingly high rate of TB worldwide.”